Sign In  |  Register  |  About San Rafael  |  Contact Us

San Rafael, CA
September 01, 2020 1:37pm
7-Day Forecast | Traffic

  • Search Hotels in San Rafael

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Turning Point Therapeutics Inc (NQ: TPTX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 16, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Turning Point Therapeutics Inc

< Previous 1 2 Next >
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers 
Via Benzinga
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal 
Via Benzinga
Turning Point Reveals Topline Data From Pivotal Repotrectinib Trial In Lung Cancer Setting
Turning Point Therapeutics Inc (NASDAQ: TPTX)  
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Trevi Therapeutics (NASDAQ:TRVI) ... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
FDA Clears Turning Point's IND For Elzovantinib + Aumolertinib Combo Regime In Lung Cancer Setting
The FDA has signed off Turning Point Therapeutics Inc's (NASDAQ: TPTX) Investigational New Drug (IND) application for elzovantinib + aumolertinib combo therapy... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows. Noteable 52-Week Lows: Intuitive Surgical (NASDAQ:ISRG) is the largest company in terms of market cap to... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021
Upgrades For CarMax Inc (NYSE: 
Via Benzinga
The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs
Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific news.... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
The Daily Biotech Pulse: Moderna Awaits Adcom Ruling On COVID-19 Booster Shot; Teligent Files For Chapter 11; CFO Transitions at Catalyst Biosciences, CRISPR; Lucid Diagnostics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Catalyst Biosciences Announces Resignation Of CFO Catalyst Biosciences, Inc... 
Via Benzinga
Exposures COVID-19
10 Biggest Price Target Changes For Tuesday
Evercore ISI Group raised Lear Corporation (NYSE: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2021
Upgrades According to Vertical Research, the prior rating for C.H. Robinson Worldwide Inc (NASDAQ: 
Via Benzinga
Turning Point Reveals Early Repotrectinib Data In NTRK+ Advanced Solid Tumors
Turning Point Therapeutics Inc (NASDAQ: TPTX) announced early data from TRIDENT-1 Phase 1/2 study of its lead drug candidate repotrectinib. In the NTRK-positive TKI-na... 
Via Benzinga
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Exposures Product Safety
45 Biggest Movers From Yesterday
Gainers Camber Energy, Inc.. (NYSE: CEI) shares surged 95.9% to close at $1.78 on Thursday after dipping over 40% on Wednesday. Camber Energy filed amended 8K showing financial... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Nanobiotix (NASDAQ:NBTX) shares rose 13.2% to $12.0 during Thursday's regular session. The market value of their outstanding shares is at $417.9 million.... 
Via Benzinga
Turning Point Shares Plunge After Highlighting Updated Data From Lead Program In Pretreated Lung Cancer Patients
Turning Point Therapeutics Inc (NASDAQ: TPTX) has announced additional preliminary data from ongoing trials of lead drug candidate repotrectinib and elzovantinib (... 
Via Benzinga
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
Via Benzinga
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs, And More
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Here are the key catalysts that could move stocks in the unfolding... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co... 
Via Benzinga
Exposures Product Safety
Turning Point's TPX-0022 In Gastric Cancer Gets Orphan Drug Designation In US
The FDA has granted Orphan Drug Designation to Turning Point Therapeutics Inc's (NASDAQ: TPTX) TPX-0022, for gastric cancer, including gastroesophageal... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
Upgrades For Cabot Oil & Gas Corp (NYSE:COG),... 
Via Benzinga
85 Biggest Movers From Yesterday
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX... 
Via Benzinga
54 Stocks Moving In Tuesday's Mid-Day Session
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) climbed 79.3% to $14.93 after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy... 
Via Benzinga
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •... 
Via Benzinga
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanRafael.com & California Media Partners, LLC. All rights reserved.